Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.

iScience·2026
Same author

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

NPJ precision oncology·2026
Same author

Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells.

Cancers·2026
Same author

A meta-analytic review of cultural variation in affect valuation.

Psychological bulletin·2026
Same author

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Molecular cancer therapeutics·2025
Same author

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Molecular cancer therapeutics·2025

Related Experiment Video

Updated: Jun 8, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Molecular biomarker analyses using circulating tumor cells.

Elizabeth A Punnoose1, Siminder K Atwal, Jill M Spoerke

  • 1Department of Oncology Biomarker Development, Genentech, Inc, South San Francisco, California, United States of America. punnoose.elizabeth@gene.com

Plos One
|September 15, 2010
PubMed
Summary
This summary is machine-generated.

Circulating tumor cells (CTCs) from blood enable cancer biomarker assessment. Molecular characterization of CTCs is feasible, offering real-time biomarker status, though EpCAM-based capture has limitations.

More Related Videos

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
10:12

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
10:12

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization

Published on: May 15, 2018

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Molecular Diagnostics

Background:

  • Blood-based cancer biomarker evaluation offers a less invasive alternative to tissue biopsies.
  • Circulating Tumor Cells (CTCs) in metastatic cancer patients' blood are a promising source of tumor material.

Purpose of the Study:

  • To evaluate CTC capture technologies and develop assays for molecular characterization of CTCs.
  • To assess the feasibility of real-time biomarker analysis from CTCs for clinical applications.

Main Methods:

  • Compared performance of CellSearch and two biochip platforms for CTC capture using spiked tumor cells.
  • Developed and optimized molecular assays for biomarker analysis on isolated CTCs, including HER2, KRAS, and EGFR.
  • Quantified EGFR expression and determined HER2 status in CTCs from metastatic lung and breast cancer patients, respectively.

Main Results:

  • CTC capture efficiency depends on EpCAM expression levels across tested platforms.
  • Demonstrated successful molecular characterization of CTCs for various biomarkers (HER2, gene expression, KRAS, EGFR).
  • Found high concordance (89%) for HER2 status between CTCs and tumor tissue, with discrepancies in 11% of cases. CTC counts were higher in ER+ patients, potentially due to low EpCAM and mesenchymal phenotypes.

Conclusions:

  • Molecular characterization of captured CTCs is achievable, providing potential real-time biomarker information.
  • CTCs are a valuable source for facilitating clinical biomarker evaluation.
  • Improving CTC capture efficiency, potentially by including antibodies for mesenchymal markers, is necessary for routine biomarker analysis.